ReviewJournal of diabetes investigation2026
Genetic basis of Asian diabetes.
Review in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recent genomic studies in Asian populations have advanced our understanding of the diagnosis, pathophysiology, risk prediction, and precision care of diabetes. Monogenic diabetes, including maturity-onset diabetes of the young (MODY) and mitochondrial diabetes, highlights the importance of genetic diagnosis for subtype-specific care. For type 2 diabetes (T2D), genome-wide association studies (GWAS) using large-scale biobank resources have identified numerous risk loci across the genome. These studies have emphasized characteristic features of East Asian T2D, including onset at lower BMI and relatively greater contributions from beta-cell dysfunction pathway. Genetic studies of gestational diabetes mellitus (GDM) have revealed both T2D-related and predominantly gestational components. For type 1 diabetes (T1D), population-specific HLA and non-HLA immune-related loci and possible links to infectious exposures may partly explain global variation in incidence, including lower rates in Asian populations. Polygenic risk scores (PRS) can support risk stratification for diabetes onset and complications, but their implementation in Asian populations is limited by reduced cross-population transferability. Ancestry-matched and trans-ancestry approaches are therefore needed to improve prediction and reduce disparities. Subtype-aware frameworks, including clinical clustering, pathway-specific PRS, and BMI-stratified PRS, may further improve mechanistic interpretation and prediction. Expanding genomic resources across East, Southeast, and South Asia and promoting cross-biobank studies will be essential for improving diabetes genomic research, PRS validation, and equitable precision diabetes care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.